Mesa Biotech to Present at the American Association for Clinical Chemistry Conference

SAN DIEGO, July 25, 2017 /PRNewswire/ -- Mesa Biotech, Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced that it will present at the American Association for Clinical Chemistry (AACC) 69^th Annual Scientific Meeting & Clinical Lab Expo to be held July 30 – August 3, 2017 in San Diego, California. In addition, the company will provide product demonstrations of its novel Accula^™ System for POC molecular diagnostics in Booth 543. The Accula Dock and Accula Flu A/Flu B test cassette, not yet available for sale, is currently under review at the U.S. Food and Drug Administration (FDA).    

Hong Cai, Ph.D., Co-founder and Chief Executive Officer, Mesa Biotech and Steve Young, Ph.D., Director of Research and Clinical Trials, TriCore Reference Laboratory will present 'A New, Accessible Point of Care Molecular System for the Physician Office' on August 1^st at 12:45 pm.

"Having recently filed our 510(K) submission for the Accula System with the FDA, we are excited to preview our Accula dock and disposable cassette to clinicians and potential collaborators, distributors and investors at the AACC Conference," said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. "We have worked diligently this past year hiring top talent, operationalizing our manufacturing facility, securing ISO certification, and preparing for commercial launch. These are critical precursors for both CE marking and FDA clearance."

About Mesa Biotech, Inc.

Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's Accula^™ System consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to access actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa Biotech's technology development has been funded to date by a series of grants and private equity investments.
For more information visit http://www.mesabiotech.com.

SOURCE Mesa Biotech Inc.

Related Links

http://www.mesabiotech.com